A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses

Study Overview
=================
Brief Summary
-----------------
An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to predict treatment outcome. The study is a naturalistic study of routinely prescribed antipsychotics using outcome measures undertaken as part of the routine clinical care of the cohort. These clinical data are linked with genetic information obtained from DNA and RNA from blood samples undertaken as part of the study. No alteration is made to the subjects treatment regime or medication. The study is a two stage investigation: The first stage involves the collection of a databank of clinical information and blood samples for DNA and RNA extraction from patients treated with antipsychotic medication. The second stage is a molecular genetic investigation of treatment-related genetic factors that may contribute to response prediction and predisposition to side effects. From these genetic studies pharmacogenetic prediction tests will be validated and/or developed.

Official Title
-----------------
A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses

Conditions
-----------------
Schizophrenia, Schizoaffective Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent must be obtained DSM-IV diagnosis must be one of: schizophrenia schizophreniform schizoaffective delusional disorder brief reactive psychosis psychosis not otherwise specified Ethnic origin of both parents must be known A minimum of 6 weeks continuous treatment completed with the given antipsychotic, prescribed at least at minimum recommended doses Prospectively collected outcome data available (pre-treatment and after at least 6 weeks on treatment) Exclusion criteria: Significant psychiatric or medical co-morbidity including history of: head injury with loss of consciousness seizures neurological disorder mental retardation (DSM-IV) drug or alcohol dependence (DSM-IV) serious physical illness e.g. malignancy, hepatic/renal insufficiency Concomitant psychotropic medication that may influence ratings Concomitant antipsychotics, antidepressants or mood stabilisers prescribed for >2 weeks during the antipsychotic treatment period rated

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Olanzapine<br>Subjects treated with olanzapine as part of their routine clinical care | |
| Risperidone<br>Subjects treated with risperidone as part of their routine clinical care | |
| Quetiapine<br>Subjects treated with quetiapine as part of their routine clinical care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacogenetic, DNA, RNA, Antipsychotic, Olanzapine, Risperidone, Quetiapine, Personalized medicine